The Glaucoma Implant is an innovative stent which will allow for a reduction in operative and post-operative complications and prevent blindness from Glaucoma, improving quality of life for patients.
In Australia, and throughout the world, Glaucoma is a common disease affecting nearly 2.5% of the population over the age of 45, and is the leading cause of preventable blindness.
Glaucoma management strategies rely on a reduction in the internal (intra-ocular) pressure (IOP) of the eye. The vast majority of shunts on the market are passive devices which fail due to scarring (a natural defence mechanism of the body), poor management of pressure and rejection over time, requiring significant follow up and patient management.
The development of a safe, effective and rapidly introduced Glaucoma implant would significantly benefit patients with Glaucoma. With the total annual cost of Glaucoma care reported at $1.9 billion and estimated to increase to $4.3 billion by 2025, a device to reduce risk, complications and post-operative care has significant market potential.
The device will allow for greater control over critical treatment parameters such as flow rates and absorption sites. The device also aims to reduce operative and post-operative complications, including inflammation and hypotony, a reduction in post-operative visits and an improved quality of life for patients.
Grey Innovation has partnered with The Royal Victorian Eye and Ear Hospital, a globally leading institution to evaluate the feasibility of developing an innovative surgical implant that will improve the outcome of glaucoma surgery.
This project received funding from the Victorian Government to perform a derisking feasibility study. The completed report confirmed the technical and commercial feasibility of The Glaucoma Implant.
The direct cost of Glaucoma care in Australia was $342 million, a number expected to increase as the population ages. (Access Economics Report - developed with CERA in 2005)
Access Economics Report - developed with CERA in 2005